News
New BRCA-targeting drug could treat advanced prostate cancer
The Phase II clinical trial for talazoparib, a new BRCA-targeting, precision drug, has demonstrated slowed tumour growth in some patients with advanced prostate cancer.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The Phase II clinical trial for talazoparib, a new BRCA-targeting, precision drug, has demonstrated slowed tumour growth in some patients with advanced prostate cancer.